Maravai LifeSciences Holdings, Inc. (MRVI)
NASDAQ: MRVI · IEX Real-Time Price · USD
6.84
-0.10 (-1.44%)
Jul 2, 2024, 4:00 PM EDT - Market closed
MRVI Revenue
Maravai LifeSciences Holdings had revenue of $274.10M in the twelve months ending March 31, 2024, down -61.81% year-over-year. Revenue in the quarter ending March 31, 2024 was $64.18M, a -18.79% decrease year-over-year. In the year 2023, Maravai LifeSciences Holdings had annual revenue of $288.95M, a decrease of -67.28%.
Revenue (ttm)
$274.10M
Revenue Growth
-61.81%
P/S Ratio
3.31
Revenue / Employee
$421,691
Employees
650
Market Cap
908.56M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 288.95M | -594.06M | -67.28% |
Dec 31, 2022 | 883.00M | 83.76M | 10.48% |
Dec 31, 2021 | 799.24M | 515.14M | 181.33% |
Dec 31, 2020 | 284.10M | 140.96M | 98.48% |
Dec 31, 2019 | 143.14M | 19.31M | 15.59% |
Dec 31, 2018 | 123.83M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
OPKO Health | 799.60M |
Avanos Medical | 680.10M |
Cronos Group | 93.03M |
Liquidia | 15.97M |
Autolus Therapeutics | 10.50M |
ARS Pharmaceuticals | 10.00K |
MRVI News
- 7 hours ago - Maravai Lifesciences Releases 2023 Environmental, Social and Governance (ESG) Report - GlobeNewsWire
- 12 days ago - Applied DNA and Alphazyme Conclude Linea(TM) RNAP Manufacturing Scale-up Project, Deliver Substantial Improvement in Linea(TM) IVT Platform Economics - Accesswire
- 7 weeks ago - TriLink BioTechnologies collaborates with Johns Hopkins University to establish a new RNA Innovation Center - Business Wire
- 7 weeks ago - Maravai LifeSciences Announces May and June 2024 Investor Conference Schedule - GlobeNewsWire
- 7 weeks ago - Maravai LifeSciences Reports First Quarter 2024 Financial Results - GlobeNewsWire
- 2 months ago - TriLink BioTechnologies® and Lonza Enter into Non-exclusive License and Supply Agreement for CleanCap® mRNA Capping Technology - Business Wire
- 2 months ago - TriLink BioTechnologies® Announces New San Diego Facility for Late Phase mRNA Drug Substance Production - Business Wire
- 2 months ago - Maravai LifeSciences To Host Earnings Conference Call on Wednesday, May 8, 2024 - GlobeNewsWire